Literature DB >> 26309573

Lack of association of CYP11B2-344C/T polymorphism with essential hypertension: a meta-analysis.

Jian-Fei Chen1, Jun Jing1, Hu Tan1, Min-Bao Song1, Shi-Yong Yu1, Lan Huang1.   

Abstract

OBJECTIVE: A meta-analysis was carried out to evaluate the correlation between CYP11B2-344C/T polymorphism and essential hypertension susceptibility.
METHODS: By retrieving relevant databases and collecting domestic and international literatures about the correlation between CYP11B2-344C/T polymorphism and essential hypertension, the quality of literature were evaluated according to NEWCASTLE-OTTAWA case-control study quality rating scale (NOS). RevMan 5.0 was used to select the best genetic model, analysis the heterogeneity, calculate combined OR and the 95% CI.
RESULTS: 8532 subjects were included in this study. Compared with the control group, the OR (95% CI) values of dominant model, recessive model, and additive model were 1.01 (95% CI: 0.81~1.25), 1.03 (95% CI: 0.83~1.19) and 1.10 (95% CI: 0.93-1.29).
CONCLUSION: There is no evidence to confirm that CYP11B2 (-344C/T) polymorphism is associated with susceptibility of essential hypertension.

Entities:  

Keywords:  CYP11B2; essential hypertension; meta-analysis; polymorphism

Year:  2015        PMID: 26309573      PMCID: PMC4538177     

Source DB:  PubMed          Journal:  Int J Clin Exp Med        ISSN: 1940-5901


  16 in total

1.  [Association of aldosterone synthase gene -344T/C polymorphism with plasma aldosterone and angiotensin II concentration in hypertensive patients].

Authors:  Bang-chuan Hu; Shao-li Chu; Ji-guang Wang; Zhi-hua Wang; Gu-liang Wang; Ping-jin Gao; Ding-liang Zhu
Journal:  Zhonghua Yi Xue Za Zhi       Date:  2006-04-25

2.  A unification of multivariate methods for meta-analysis of genetic association studies.

Authors:  Pantelis G Bagos
Journal:  Stat Appl Genet Mol Biol       Date:  2008-10-24

Review 3.  [Atherosclerosis (hypertension)].

Authors:  Masumi Ai
Journal:  Nihon Rinsho       Date:  2012-05

4.  Association of the -344C/T aldosterone synthase (CYP11B2) gene variant with hypertension and stroke.

Authors:  Anjana Munshi; Vandana Sharma; Subhash Kaul; K Rajeshwar; M Sai Babu; Gowhar Shafi; A N Anila; N Balakrishna; Suvarna Alladi; A Jyothy
Journal:  J Neurol Sci       Date:  2010-07-03       Impact factor: 3.181

5.  Distribution and phenotypic expression of mineralocorticoid receptor and CYP11B2 T-344C polymorphisms in a Taiwanese hypertensive population.

Authors:  Sung-Kien Sia; Hui-Ling Chiou; Shiuan-Chih Chen; Chin-Feng Tsai; Shun-Fa Yang; Kwo-Chang Ueng
Journal:  Mol Biol Rep       Date:  2012-12-29       Impact factor: 2.316

6.  [Association of aldosterone synthase gene -344 T/C polymorphism with early renal damage in Han nationality with essential hypertension].

Authors:  Xiao-jian Sun; Shao-rong Liu; Chuan-huan Zhang; Guo-hui Yuan; Hong-ying Chen; Xiao-fei Hou
Journal:  Zhonghua Yi Xue Yi Chuan Xue Za Zhi       Date:  2007-04

7.  [Correlativity between the polymorphisms of aldosterone synthase gene, Hind III restriction site on Y chromosome and essential hypertension].

Authors:  Qing-xiang Li; Hai Gao; Fang-xing Xu; Yu-qing Zhang; Hai-ying Wu; Hong-bing Yan; Guo-zhang Liu
Journal:  Zhonghua Yi Xue Yi Chuan Xue Za Zhi       Date:  2006-06

Review 8.  Hypertension, kidney, and transgenics: a fresh perspective.

Authors:  Linda J Mullins; Matthew A Bailey; John J Mullins
Journal:  Physiol Rev       Date:  2006-04       Impact factor: 37.312

9.  Genetic determination of plasma aldosterone levels in essential hypertension.

Authors:  L Pojoga; S Gautier; H Blanc; T T Guyene; O Poirier; F Cambien; A Benetos
Journal:  Am J Hypertens       Date:  1998-07       Impact factor: 2.689

10.  [Relationship between aldosterone synthase gene (CYP11B2) polymorphisms and essential hypertension in a northern Chinese Han population].

Authors:  Wen-quan Niu; Jian-bing Wang; Su-jie Li; Wen-yu Zhou; Jing-bo Zhao; Chang-chun Qiu
Journal:  Zhongguo Yi Xue Ke Xue Yuan Xue Bao       Date:  2007-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.